Abstract

Background

The prevalence of both obesity and type 2 diabetes has been on the rise in China. This randomized controlled trial was conducted to test the feasibility and effectiveness of an evidence-based diabetes prevention program in Yuci, Shanxi Province, China from 2012 to 2014.

Methods

Women with pre-diabetes, ages 25–65 y, were assigned randomly to a comparison (n=75) or 6-mo lifestyle intervention condition (n=109). Weight, fasting glucose, hemoglobin A1c and self-reported diet and physical activity were measured at baseline, 6 mo and 12 mo.

Results

All measures except fasting glucose improved favorably in both comparison and intervention participants at the 6- and 12-mo follow-ups. Participants in the intervention group lost more weight (−0.91 kg, p<0.05) and had a lower body mass index (−0.39 kg/m2, p<0.05) than the comparison group at follow-up. A total of 31.6% (31/98) and 16.2% (11/68) of the participants in the intervention and comparison groups, respectively, achieved the weight loss goal of 5% at follow-up. There was no significant group difference in outcome measures at the 12-mo follow-up. Participants in the intervention group also showed favorable changes in self-reported diet and physical activity measures.

Conclusions

A lifestyle intervention to prevent diabetes in at-risk women in community health centers in China is feasible and acceptable but effect sizes were small.

Introduction

There has been a significant global increase in type 2 diabetes, especially in developing countries. A recent study estimated that the prevalence of diabetes and pre-diabetes were 11.6% (12.1% for men and 11% for women) and 50.1% (52.1% for men and 48.1% for women), respectively, in China in 2010.1 Health and economic burdens associated with diabetes have posed substantial challenges to the healthcare systems in low- and middle-income countries. There is an urgent need to develop evidence-based prevention programs to address these challenges in China and other developing countries. However, previous efforts in translating evidence-based interventions to racial/ethnic minority and non-Western populations have produced mixed results.2,3

Randomized controlled trials (RCTs) such as the Chinese Da Qing Impaired Glucose Tolerance and Diabetes Study (CDQDPOS),4 the US Diabetes Prevention Program (DPP)5 and the Finnish Diabetes Prevention Study (DPS)6 have demonstrated the efficacy of intensive lifestyle intervention in the reduction of risks and the incidence of diabetes in pre-diabetic populations. Translation of DPP and DPS as evidence-based interventions has produced promising outcomes in healthcare and community settings in high-income countries.7

Recently the Chinese government has restructured its healthcare system to address the increase in lifestyle-related chronic diseases. In 2006 the Ministry of Health officially endorsed the Community Health Service system and began to promote the urban primary healthcare model through Community Health Centers (CHCs) and Community Health Stations (CHSs), using a six-in-one model: clinical care, health education, family planning, rehabilitation, health maintenance and prevention.8 The cities are divided into communities of 10 000–25 000 individuals with one CHC or CHS per community, with the health workers being responsible for screening and managing chronic disease for all members of their community. The newly initiated Community Health Service system has opened a new venue for conducting community-based health promotion programs that can aggressively attack diabetes in China using the latest advancements in diabetes prevention and translation research.

We conducted a translation study to evaluate a community-based lifestyle intervention program, Pathway to Health (PATH), to reduce the risk of diabetes in a sample of Chinese women at risk for diabetes. The purposes of this RCT were to test the feasibility and acceptability of adapting the DPP curriculum for implementation in CHCs by trained community health educators and to test the effects of a 6-mo intervention on body weight, hemoglobin A1c (HbA1c) and cardiorespiratory fitness at 6- and 12-mo follow-ups. Clinical indicators such as the percentage of participants achieving a 5% weight loss and a 10% reduction in HbA1c and the number needed to treat were examined. We also examined the effect of program attendance on the outcome measures.

Materials and methods

Study design and sample

This 1-y RCT was conducted in a non-metropolitan community in collaboration with the local health department, municipal hospital and two CHCs in Yuci, Shanxi Province, China from May 2013 to November 2014. Study outcomes were assessed at baseline and the 6- and 12-mo follow-ups. The majority of the study participants were recruited from patients enrolled in two CHCs. We also recruited participants from a hospital-based health screening center that offers annual health screenings to community residents for a fee. The study eligibility criteria were female residents aged 25–65 y, pre-diabetes (based on a previous health exam), overweight or obese (body mass index [BMI]≥24), not physically active (based on a short physical activity [PA] screening)9 and expressed interest in lifestyle changes. Individuals who had diagnosed diabetes or reported the use of medication for diabetes were excluded from the study. All participants completed a preliminary eligibility screening and provided informed consent. After completing the baseline assessment, the participants in two cohorts were assigned randomly to either a comparison group (40%) or a 6-mo lifestyle intervention group (60%), in blocks of 10 participants, using a randomization table by the study statistician. Enrollment and randomization were performed by trained research staff. There was no contact with the participants during the last 6 mo of the study. We planned to recruit 280 female participants, which would provide an 80% power (α=0.05 for a two-tailed test) to detect a moderate intervention effect (δ=0.4–0.6) on weight loss, assuming a retention rate of 90% over three measurement points. The study protocol was approved by the Institutional Review Board at the University of Texas at San Antonio and North Dakota State University. Because it was not stipulated by the funding agencies, this study was not registered as a clinical trial.

Study outcome and process measurements

Trained research staff measured the participant’s weight, height and waist circumference with light clothes twice and the average was used. Venous blood plasma was collected for HbA1c and fasting glucose after an 8-h fast. The blood samples were assayed at the city’s municipal hospital. Heart rate (beats per minute [bpm]) at the completion of a submaximal 3-min step test was used to evaluate cardiorespiratory fitness.10 Information on clinical indicators (percentage of participants losing ≥5% of body weight and lowering HbA1c ≥10%) was also assessed.

Lifestyle factors, including physical activity and diet, were assessed. The participants completed the International Physical Activity Questionnaire – Short Form (IPAQ-SF), which provides estimates of habitual levels (min/d) of vigorous PA (VPA), moderate PA (MPA) and walking for exercise in the last 7 d.11 Because VPA was not reported by the participants, we only analysed the minutes for MPA and walking. The participants also completed a dietary survey to assess the eating habits and quality of diet based on the Chinese Dietary Guidelines.12 The 40-question survey assessed meal and snack patterns; the kind and amount of staple and beverage consumption; the frequency of dairy, meat, organ meat, fish, legume, fruit and vegetable consumption and cooking methods (e.g., fried, stir fried, steamed, boiled). The scores ranged from 50 to 200, with higher scores indicating a higher-quality diet. Attendance in group health education classes was recorded. Demographics (age, marital status, work status, childcare responsibilities), family history of diabetes, menopause status, medication use and new diagnoses of diabetes were also collected.

Description of the intervention treatments

PATH intervention

The PATH was a group-based lifestyle intervention built on the DPP Group Lifestyle Balance program13 and a feasibility study of a community-based lifestyle modification program for diabetes risk reduction in Mexican American women at risk for diabetes in San Antonio, TX, USA.14 PATH was a goal-based behavioral intervention with three goals: 5% weight loss, ≥30 min of MPA (3000–4000 moderate-intensity steps/d or an equivalent amount of other forms of PA) on most days of the week and a reduction in weekly caloric intake of 1000–1400 calories (200 calories/d) by adopting healthy eating practices (limiting foods high in fat and starch and increasing vegetables and fruits). PATH participants received training to individualize the three goals into short- and long-term goals and re-evaluate the goals with the support of Community Health Educators (CHEs). For example, each participant identified the 5% weight goal based on her weight at baseline and developed short-term weight loss goals. Intervention activities were adapted to address differences in lifestyle and culture, traditional values associated with foods (e.g., preference for high starch foods), cooking practices, resources available and healthcare practices in China. We also modified the nutritional messages and recommendations based on the Chinese Food Guide Pagoda.15 PATH program materials are available for public use at http://www.pathdpp.com.

The 6-mo intervention included 12 large-group health education sessions on nutrition, PA, behavioral monitoring/goal setting; 10 small-group sessions for goal setting and evaluation, counselling and social support; and a final celebration party. The intervention was delivered by CHEs who were recruited from the chronic disease management team in the two CHCs. The CHEs received 50 h of training in lifestyle interventions, PA, nutrition and community-based health promotion. At the beginning of the intervention the participants established their personalized behavioral goals and identified strategies to achieve the goals under the guidance of the CHEs in a PATH Participant’s Handbook, which included a PATH description, individual goal worksheets, weekly logs and class handouts. The participants received training on walking with a pedometer and strengthening exercises with a resistance band, an exercise DVD for exercise at home, an oil and salt measuring cup to monitor the amount of oil and salt used in cooking and information on healthy cooking with recipes for reducing starch and fat intake. The class topics and schedules are shown in Table 1. Participant’s weight was recorded at each meeting. CHEs also made weekly phone calls to the participants for problem solving and support if they missed a session. The participants used the PATH Handbook to record their goal progress and monitor their weekly dietary and physical activities.

Table 1.

PATH health education class and small-group meeting schedule

Week no.Meeting type and topic
Week 1Class 1: Starting on the PATH to health—are you ready? (Importance of physical activity and diet)
Week 2Class 2: Starting on the PATH to health: changing your lifestyle
Week 3Class 3: Knowing how much you move
Week 4Small group: Activity form, goals, food diary
Week 5Class 4: Nutrition (Healthy eating—the Chinese food pyramid)
Week 6Small group: Review game, food diary, self-evaluation and goals
Week 7Class 5: Being active: a way of life
Week 8Small group: Review, activity form, resistance band (DVD)
Week 9Class 6: Nutrition: carbohydrates
Week 10Small group: Review game (Jeopardy), food diary, self-evaluation, resistance band
Week 11Class 7: Nutrition: protein
Week 12Small group: Basic cooking skills, food diary
Week 13Class 8: Nutrition: tip the calorie balance
Week 14Small group: Review game (Jeopardy), self-evaluation
Week 15Class 9: Problem solving
Week 16Small group: Self-evaluation, problem solving
Week 17Class 10: Managing your environment
Week 18Small group: Food labels
Week 19Class 11: The slippery slope of lifestyle change
Week 20Small group: Menopause discussion
Week 21Class 12: Ways to stay motivated
Week 22Small group: Wheel of fortune game
Week 23Celebration
Week no.Meeting type and topic
Week 1Class 1: Starting on the PATH to health—are you ready? (Importance of physical activity and diet)
Week 2Class 2: Starting on the PATH to health: changing your lifestyle
Week 3Class 3: Knowing how much you move
Week 4Small group: Activity form, goals, food diary
Week 5Class 4: Nutrition (Healthy eating—the Chinese food pyramid)
Week 6Small group: Review game, food diary, self-evaluation and goals
Week 7Class 5: Being active: a way of life
Week 8Small group: Review, activity form, resistance band (DVD)
Week 9Class 6: Nutrition: carbohydrates
Week 10Small group: Review game (Jeopardy), food diary, self-evaluation, resistance band
Week 11Class 7: Nutrition: protein
Week 12Small group: Basic cooking skills, food diary
Week 13Class 8: Nutrition: tip the calorie balance
Week 14Small group: Review game (Jeopardy), self-evaluation
Week 15Class 9: Problem solving
Week 16Small group: Self-evaluation, problem solving
Week 17Class 10: Managing your environment
Week 18Small group: Food labels
Week 19Class 11: The slippery slope of lifestyle change
Week 20Small group: Menopause discussion
Week 21Class 12: Ways to stay motivated
Week 22Small group: Wheel of fortune game
Week 23Celebration
Table 1.

PATH health education class and small-group meeting schedule

Week no.Meeting type and topic
Week 1Class 1: Starting on the PATH to health—are you ready? (Importance of physical activity and diet)
Week 2Class 2: Starting on the PATH to health: changing your lifestyle
Week 3Class 3: Knowing how much you move
Week 4Small group: Activity form, goals, food diary
Week 5Class 4: Nutrition (Healthy eating—the Chinese food pyramid)
Week 6Small group: Review game, food diary, self-evaluation and goals
Week 7Class 5: Being active: a way of life
Week 8Small group: Review, activity form, resistance band (DVD)
Week 9Class 6: Nutrition: carbohydrates
Week 10Small group: Review game (Jeopardy), food diary, self-evaluation, resistance band
Week 11Class 7: Nutrition: protein
Week 12Small group: Basic cooking skills, food diary
Week 13Class 8: Nutrition: tip the calorie balance
Week 14Small group: Review game (Jeopardy), self-evaluation
Week 15Class 9: Problem solving
Week 16Small group: Self-evaluation, problem solving
Week 17Class 10: Managing your environment
Week 18Small group: Food labels
Week 19Class 11: The slippery slope of lifestyle change
Week 20Small group: Menopause discussion
Week 21Class 12: Ways to stay motivated
Week 22Small group: Wheel of fortune game
Week 23Celebration
Week no.Meeting type and topic
Week 1Class 1: Starting on the PATH to health—are you ready? (Importance of physical activity and diet)
Week 2Class 2: Starting on the PATH to health: changing your lifestyle
Week 3Class 3: Knowing how much you move
Week 4Small group: Activity form, goals, food diary
Week 5Class 4: Nutrition (Healthy eating—the Chinese food pyramid)
Week 6Small group: Review game, food diary, self-evaluation and goals
Week 7Class 5: Being active: a way of life
Week 8Small group: Review, activity form, resistance band (DVD)
Week 9Class 6: Nutrition: carbohydrates
Week 10Small group: Review game (Jeopardy), food diary, self-evaluation, resistance band
Week 11Class 7: Nutrition: protein
Week 12Small group: Basic cooking skills, food diary
Week 13Class 8: Nutrition: tip the calorie balance
Week 14Small group: Review game (Jeopardy), self-evaluation
Week 15Class 9: Problem solving
Week 16Small group: Self-evaluation, problem solving
Week 17Class 10: Managing your environment
Week 18Small group: Food labels
Week 19Class 11: The slippery slope of lifestyle change
Week 20Small group: Menopause discussion
Week 21Class 12: Ways to stay motivated
Week 22Small group: Wheel of fortune game
Week 23Celebration

All intervention sessions lasted 60 min and were conducted at two CHCs and a health screening center. The health education session began with a weigh-in and review of the step count for the previous week, followed by a review of the previous class content, a 30-min lecture (using participatory teaching methods) and finally a discussion. Small-group meetings were attended by three to five participants and included a review of previous material, discussion of issues related to topics of previous lectures, sharing of problem-solving strategies and evaluation of individual goals. Voluntary resistance band exercise sessions were offered 30 min before class time from week 8. Participants in the intervention group were allowed to make up missed health classes at a later time.

Comparison group: general healthy lifestyle education

Participants in the comparison group received a counselling session with a nurse to review the results of the baseline testing, a package with information on nutrition and PA, a pedometer with instructions, an oil and salt measuring cup and a notebook for taking notes at health classes and for tracking weight and PA, but they were not given specific counselling or reinforcement to do so. The participants were invited to attend six general health education classes on PA, nutrition, chronic diseases (obesity, diabetes, heart diseases) and menopause at the same venue as the intervention group. The sessions were 3–4 wk apart and lasted about 1 h. The participants did not have small-group meetings or group exercise sessions.

Data analysis

Demographic, baseline outcome and process measures were tested with a one-way F test for continuous variables and χ2 test for categorical variables to examine the difference between the comparison and intervention groups. Generalized estimation equations (GEEs) for repeated measures were used to test the time effect as well as the time×treatment interaction on differences in the outcome measures, with planned contrasts between the comparison and intervention groups at the 6- and 12-mo follow-ups. One random effect was included in the model to account for the autocorrelations from repeated measurements. Cohort, demographic (age, education, marital status, and childcare) and health history variables (menopause status and medication use), as fixed effects, were included as covariates in the model. Similarly, we tested the difference in self-reported PA and dietary quality between the comparison and intervention groups. We also explored the effect of program attendance (<70% vs ≥70% session attendance) on the outcome measures and self-reported behavioral measures. The significance level was set at p<0.05 (two-sided test). SPSS Statistics 22 (IBM, Armonk, NY, USA) was used for all data analysis.

Results

Baseline

The flow of study participants is displayed in Figure 1. After completing baseline assessment, 184 participants were randomized to an intervention or comparison group. Participant retention rates were 95% (n=174) at the 6-mo follow-up and 86% (n=159) at the 12-mo follow-up.

PATH participants flow diagram.
Figure 1.

PATH participants flow diagram.

Participant characteristics are shown in Table 2. The average age of the participants was 51.96 y (SD 7.22), with two-thirds being postmenopausal. Half of the participants had less than a high school education (≤9 y of school). Almost all participants were married, and nearly half had the responsibility of taking care of a grandchild. The health history of the participants demonstrated a high-risk profile for diabetes. Close to one-third had a family history of diabetes (n=57), 26% (n=48) were taking medication for hypertension and 69.9% (n=124) had metabolic syndrome.16 There was no difference in the outcome measures, self-reported MPA and walking between the comparison and intervention groups at baseline, except heart rate response to the step test, with the participants in the comparison group being less fit.

Table 2.

Comparisons of study participant characteristics and outcome measures at baselinea

Study variable nameComparison group (n=75)Intervention group (n=109)All
(n=184)
Age (y), mean (SD)**53.27 (7.17)51.06 (7.15)51.96 (7.22)
Study cohort, n (%)133 (44.0)51 (46.8)84 (45.7)
242 (56.0)58 (53.2)100 (54.3)
Education, n (%)**1–6 y10 (13.3)13 (11.9)23 (12.5)
7–9 y36 (48.0)33 (30.3)69 (37.5)
10–12 y23 (30.7)33 (30.3)56 (30.4)
≥13 y6 (8.0)30 (27.5)36 (19.6)
Marriage status, n (%)Married72 (96.0)104 (95.4)176 (95.7)
Not married3 (4.0)5 (4.6)8 (4.3)
Childcare responsibility, n (%)No44 (58.7)58 (53.2)102 (55.4)
Yes31 (41.3)51 (46.8)82 (44.6)
Family diabetes history, n (%)No57 (76.0)70 (64.2)127 (69.0)
Yes18 (24.0)39 (35.8)57 (31.0)
Menopause status, n (%)No22 (29.3)38 (34.9)60 (32.6)
Yes53 (70.7)71 (65.1)124 (67.4)
Taking hypertension medication, n (%)No57 (76.0)79 (72.5)136 (73.9)
Yes18 (24.0)30 (27.5)48 (26.1)
Taking lipids medication, n (%)No71 (94.7)105 (96.3)176 (95.7)
Yes4 (5.3)4 (3.7)8 (4.3)
Metabolic syndrome, n (%)*No17 (22.7)39 (35.8)56 (30.4)
Yes58 (77.3)70 (64.2)128 (69.6)
Weight (kg), mean (SD)68.59 (8.42)67.82 (9.10)68.13 (8.81)
Waist circumference (cm), mean (SD)96.95 (7.27)95.41 (7.41)96.04 (7.37)
BMI (kg/m2), mean (SD)27.43 (2.75)27.42 (2.91)27.42 (2.84)
HbA1c (%), mean (SD)6.04 (0.45)6.04 (0.51)6.04 (0.49)
Fasting glucose, mean (SD)5.38 (0.53)5.38 (0.59)5.38 (0.57)
Heart rate in the step test (bpm), mean (SD)**139.32 (13.61)134.66 (15.06)136.52 (14.64)
Diet quality score, mean (SD)*105.43(11.37)102.16 (12.25)103.50 (11.97)
Daily self-reported moderate physical activity, n (%)*<30 min/d67 (89.3)99 (90.8)166 (90.2)
30–59 min/d2 (2.7)8 (7.3)10 (5.4)
≥60 min/d6 (8.0)2 (1.8)8 (4.3)
Daily self-reported walking, n (%)<30 min/d51 (68.0)76 (72.4)127 (70.6)
30–59 min/d13 (17.3)12 (11.4)25 (13.9)
≥60 min/d11 (14.7)17 (16.2)28 (15.6)
Study variable nameComparison group (n=75)Intervention group (n=109)All
(n=184)
Age (y), mean (SD)**53.27 (7.17)51.06 (7.15)51.96 (7.22)
Study cohort, n (%)133 (44.0)51 (46.8)84 (45.7)
242 (56.0)58 (53.2)100 (54.3)
Education, n (%)**1–6 y10 (13.3)13 (11.9)23 (12.5)
7–9 y36 (48.0)33 (30.3)69 (37.5)
10–12 y23 (30.7)33 (30.3)56 (30.4)
≥13 y6 (8.0)30 (27.5)36 (19.6)
Marriage status, n (%)Married72 (96.0)104 (95.4)176 (95.7)
Not married3 (4.0)5 (4.6)8 (4.3)
Childcare responsibility, n (%)No44 (58.7)58 (53.2)102 (55.4)
Yes31 (41.3)51 (46.8)82 (44.6)
Family diabetes history, n (%)No57 (76.0)70 (64.2)127 (69.0)
Yes18 (24.0)39 (35.8)57 (31.0)
Menopause status, n (%)No22 (29.3)38 (34.9)60 (32.6)
Yes53 (70.7)71 (65.1)124 (67.4)
Taking hypertension medication, n (%)No57 (76.0)79 (72.5)136 (73.9)
Yes18 (24.0)30 (27.5)48 (26.1)
Taking lipids medication, n (%)No71 (94.7)105 (96.3)176 (95.7)
Yes4 (5.3)4 (3.7)8 (4.3)
Metabolic syndrome, n (%)*No17 (22.7)39 (35.8)56 (30.4)
Yes58 (77.3)70 (64.2)128 (69.6)
Weight (kg), mean (SD)68.59 (8.42)67.82 (9.10)68.13 (8.81)
Waist circumference (cm), mean (SD)96.95 (7.27)95.41 (7.41)96.04 (7.37)
BMI (kg/m2), mean (SD)27.43 (2.75)27.42 (2.91)27.42 (2.84)
HbA1c (%), mean (SD)6.04 (0.45)6.04 (0.51)6.04 (0.49)
Fasting glucose, mean (SD)5.38 (0.53)5.38 (0.59)5.38 (0.57)
Heart rate in the step test (bpm), mean (SD)**139.32 (13.61)134.66 (15.06)136.52 (14.64)
Diet quality score, mean (SD)*105.43(11.37)102.16 (12.25)103.50 (11.97)
Daily self-reported moderate physical activity, n (%)*<30 min/d67 (89.3)99 (90.8)166 (90.2)
30–59 min/d2 (2.7)8 (7.3)10 (5.4)
≥60 min/d6 (8.0)2 (1.8)8 (4.3)
Daily self-reported walking, n (%)<30 min/d51 (68.0)76 (72.4)127 (70.6)
30–59 min/d13 (17.3)12 (11.4)25 (13.9)
≥60 min/d11 (14.7)17 (16.2)28 (15.6)

*p<0.10, **p<0.05.

aGroup differences were tested with one-way F test for continuous variables and χ2 test for categorical variables.

Table 2.

Comparisons of study participant characteristics and outcome measures at baselinea

Study variable nameComparison group (n=75)Intervention group (n=109)All
(n=184)
Age (y), mean (SD)**53.27 (7.17)51.06 (7.15)51.96 (7.22)
Study cohort, n (%)133 (44.0)51 (46.8)84 (45.7)
242 (56.0)58 (53.2)100 (54.3)
Education, n (%)**1–6 y10 (13.3)13 (11.9)23 (12.5)
7–9 y36 (48.0)33 (30.3)69 (37.5)
10–12 y23 (30.7)33 (30.3)56 (30.4)
≥13 y6 (8.0)30 (27.5)36 (19.6)
Marriage status, n (%)Married72 (96.0)104 (95.4)176 (95.7)
Not married3 (4.0)5 (4.6)8 (4.3)
Childcare responsibility, n (%)No44 (58.7)58 (53.2)102 (55.4)
Yes31 (41.3)51 (46.8)82 (44.6)
Family diabetes history, n (%)No57 (76.0)70 (64.2)127 (69.0)
Yes18 (24.0)39 (35.8)57 (31.0)
Menopause status, n (%)No22 (29.3)38 (34.9)60 (32.6)
Yes53 (70.7)71 (65.1)124 (67.4)
Taking hypertension medication, n (%)No57 (76.0)79 (72.5)136 (73.9)
Yes18 (24.0)30 (27.5)48 (26.1)
Taking lipids medication, n (%)No71 (94.7)105 (96.3)176 (95.7)
Yes4 (5.3)4 (3.7)8 (4.3)
Metabolic syndrome, n (%)*No17 (22.7)39 (35.8)56 (30.4)
Yes58 (77.3)70 (64.2)128 (69.6)
Weight (kg), mean (SD)68.59 (8.42)67.82 (9.10)68.13 (8.81)
Waist circumference (cm), mean (SD)96.95 (7.27)95.41 (7.41)96.04 (7.37)
BMI (kg/m2), mean (SD)27.43 (2.75)27.42 (2.91)27.42 (2.84)
HbA1c (%), mean (SD)6.04 (0.45)6.04 (0.51)6.04 (0.49)
Fasting glucose, mean (SD)5.38 (0.53)5.38 (0.59)5.38 (0.57)
Heart rate in the step test (bpm), mean (SD)**139.32 (13.61)134.66 (15.06)136.52 (14.64)
Diet quality score, mean (SD)*105.43(11.37)102.16 (12.25)103.50 (11.97)
Daily self-reported moderate physical activity, n (%)*<30 min/d67 (89.3)99 (90.8)166 (90.2)
30–59 min/d2 (2.7)8 (7.3)10 (5.4)
≥60 min/d6 (8.0)2 (1.8)8 (4.3)
Daily self-reported walking, n (%)<30 min/d51 (68.0)76 (72.4)127 (70.6)
30–59 min/d13 (17.3)12 (11.4)25 (13.9)
≥60 min/d11 (14.7)17 (16.2)28 (15.6)
Study variable nameComparison group (n=75)Intervention group (n=109)All
(n=184)
Age (y), mean (SD)**53.27 (7.17)51.06 (7.15)51.96 (7.22)
Study cohort, n (%)133 (44.0)51 (46.8)84 (45.7)
242 (56.0)58 (53.2)100 (54.3)
Education, n (%)**1–6 y10 (13.3)13 (11.9)23 (12.5)
7–9 y36 (48.0)33 (30.3)69 (37.5)
10–12 y23 (30.7)33 (30.3)56 (30.4)
≥13 y6 (8.0)30 (27.5)36 (19.6)
Marriage status, n (%)Married72 (96.0)104 (95.4)176 (95.7)
Not married3 (4.0)5 (4.6)8 (4.3)
Childcare responsibility, n (%)No44 (58.7)58 (53.2)102 (55.4)
Yes31 (41.3)51 (46.8)82 (44.6)
Family diabetes history, n (%)No57 (76.0)70 (64.2)127 (69.0)
Yes18 (24.0)39 (35.8)57 (31.0)
Menopause status, n (%)No22 (29.3)38 (34.9)60 (32.6)
Yes53 (70.7)71 (65.1)124 (67.4)
Taking hypertension medication, n (%)No57 (76.0)79 (72.5)136 (73.9)
Yes18 (24.0)30 (27.5)48 (26.1)
Taking lipids medication, n (%)No71 (94.7)105 (96.3)176 (95.7)
Yes4 (5.3)4 (3.7)8 (4.3)
Metabolic syndrome, n (%)*No17 (22.7)39 (35.8)56 (30.4)
Yes58 (77.3)70 (64.2)128 (69.6)
Weight (kg), mean (SD)68.59 (8.42)67.82 (9.10)68.13 (8.81)
Waist circumference (cm), mean (SD)96.95 (7.27)95.41 (7.41)96.04 (7.37)
BMI (kg/m2), mean (SD)27.43 (2.75)27.42 (2.91)27.42 (2.84)
HbA1c (%), mean (SD)6.04 (0.45)6.04 (0.51)6.04 (0.49)
Fasting glucose, mean (SD)5.38 (0.53)5.38 (0.59)5.38 (0.57)
Heart rate in the step test (bpm), mean (SD)**139.32 (13.61)134.66 (15.06)136.52 (14.64)
Diet quality score, mean (SD)*105.43(11.37)102.16 (12.25)103.50 (11.97)
Daily self-reported moderate physical activity, n (%)*<30 min/d67 (89.3)99 (90.8)166 (90.2)
30–59 min/d2 (2.7)8 (7.3)10 (5.4)
≥60 min/d6 (8.0)2 (1.8)8 (4.3)
Daily self-reported walking, n (%)<30 min/d51 (68.0)76 (72.4)127 (70.6)
30–59 min/d13 (17.3)12 (11.4)25 (13.9)
≥60 min/d11 (14.7)17 (16.2)28 (15.6)

*p<0.10, **p<0.05.

aGroup differences were tested with one-way F test for continuous variables and χ2 test for categorical variables.

Primary study outcomes: weight and cardiometabolic indicators

All outcome measures except fasting glucose improved from baseline to the 6-mo follow-up and from baseline to the 12-mo follow-up in participants in both groups. Fasting glucose increased across time in both the comparison and intervention groups. The results of GEE analysis (see Table 3) revealed a significant time effect on the outcome measures with adjustment for multiple comparisons, suggesting participants in both groups had favorable changes over the study period. There was a significant time×treatment interaction on the changes in body weight and BMI at the 6-mo follow-up that favored the intervention participants, after adjustment for covariates. No other group difference was found at the 6- and 12-mo follow-ups.

Table 3.

Estimated marginal means (M) and standard errors (SE) for study outcome measures at baseline and 6- and 12-mo follow-ups

Outcome measuresAll participants†Comparison groupIntervention groupGroup difference at 6 mo‡Group difference 12 mo‡
Baseline6 mo12 moBaseline6 mo12 moBaseline6 mo12 mo
Weight (kg)M67.32a,b66.08a66.45b67.51b66.72b66.82b67.13b65.44b66.07b0.91*0.38
SE0.740.770.771.131.181.170.880.920.920.450.45
BMI (kg/m2)M27.20a,b26.71a26.87b27.1926.9026.9427.2026.5226.800.39*0.16
SE0.220.240.240.340.360.370.280.300.310.180.18
Waist circumference (cm)M94.86a,b93.39a93.96b95.5894.4595.0894.1492.3392.840.680.80
SE0.600.630.600.870.940.890.740.790.750.690.60
HbA1c (%)M5.99a,b5.78a5.66b5.965.765.66.025.85.710.01–0.05
SE0.040.040.040.060.060.060.050.050.050.080.09
Fasting glucose (mmol/l)M5.3a,b5.49a5.63b5.265.445.625.345.555.63–0.040.07
SE0.050.040.050.070.070.070.060.050.050.080.08
Heart rate (bpm)M138.05a,b131.54a133.89b140.33134.60137.56135.77128.49130.221.542.77
SE1.261.291.221.881.931.811.541.571.481.941.97
Outcome measuresAll participants†Comparison groupIntervention groupGroup difference at 6 mo‡Group difference 12 mo‡
Baseline6 mo12 moBaseline6 mo12 moBaseline6 mo12 mo
Weight (kg)M67.32a,b66.08a66.45b67.51b66.72b66.82b67.13b65.44b66.07b0.91*0.38
SE0.740.770.771.131.181.170.880.920.920.450.45
BMI (kg/m2)M27.20a,b26.71a26.87b27.1926.9026.9427.2026.5226.800.39*0.16
SE0.220.240.240.340.360.370.280.300.310.180.18
Waist circumference (cm)M94.86a,b93.39a93.96b95.5894.4595.0894.1492.3392.840.680.80
SE0.600.630.600.870.940.890.740.790.750.690.60
HbA1c (%)M5.99a,b5.78a5.66b5.965.765.66.025.85.710.01–0.05
SE0.040.040.040.060.060.060.050.050.050.080.09
Fasting glucose (mmol/l)M5.3a,b5.49a5.63b5.265.445.625.345.555.63–0.040.07
SE0.050.040.050.070.070.070.060.050.050.080.08
Heart rate (bpm)M138.05a,b131.54a133.89b140.33134.60137.56135.77128.49130.221.542.77
SE1.261.291.221.881.931.811.541.571.481.941.97

Same superscripted letters denote group difference (all p<0.05 with Bonferroni adjustment for multiple comparisons).

*p<0.05.

†One-way post hoc test for time effect between baseline and 6-mo follow-up and baseline and 12-mo follow-up.

‡Planned contrast for group difference at 6- and 12-mo follow-ups.

Table 3.

Estimated marginal means (M) and standard errors (SE) for study outcome measures at baseline and 6- and 12-mo follow-ups

Outcome measuresAll participants†Comparison groupIntervention groupGroup difference at 6 mo‡Group difference 12 mo‡
Baseline6 mo12 moBaseline6 mo12 moBaseline6 mo12 mo
Weight (kg)M67.32a,b66.08a66.45b67.51b66.72b66.82b67.13b65.44b66.07b0.91*0.38
SE0.740.770.771.131.181.170.880.920.920.450.45
BMI (kg/m2)M27.20a,b26.71a26.87b27.1926.9026.9427.2026.5226.800.39*0.16
SE0.220.240.240.340.360.370.280.300.310.180.18
Waist circumference (cm)M94.86a,b93.39a93.96b95.5894.4595.0894.1492.3392.840.680.80
SE0.600.630.600.870.940.890.740.790.750.690.60
HbA1c (%)M5.99a,b5.78a5.66b5.965.765.66.025.85.710.01–0.05
SE0.040.040.040.060.060.060.050.050.050.080.09
Fasting glucose (mmol/l)M5.3a,b5.49a5.63b5.265.445.625.345.555.63–0.040.07
SE0.050.040.050.070.070.070.060.050.050.080.08
Heart rate (bpm)M138.05a,b131.54a133.89b140.33134.60137.56135.77128.49130.221.542.77
SE1.261.291.221.881.931.811.541.571.481.941.97
Outcome measuresAll participants†Comparison groupIntervention groupGroup difference at 6 mo‡Group difference 12 mo‡
Baseline6 mo12 moBaseline6 mo12 moBaseline6 mo12 mo
Weight (kg)M67.32a,b66.08a66.45b67.51b66.72b66.82b67.13b65.44b66.07b0.91*0.38
SE0.740.770.771.131.181.170.880.920.920.450.45
BMI (kg/m2)M27.20a,b26.71a26.87b27.1926.9026.9427.2026.5226.800.39*0.16
SE0.220.240.240.340.360.370.280.300.310.180.18
Waist circumference (cm)M94.86a,b93.39a93.96b95.5894.4595.0894.1492.3392.840.680.80
SE0.600.630.600.870.940.890.740.790.750.690.60
HbA1c (%)M5.99a,b5.78a5.66b5.965.765.66.025.85.710.01–0.05
SE0.040.040.040.060.060.060.050.050.050.080.09
Fasting glucose (mmol/l)M5.3a,b5.49a5.63b5.265.445.625.345.555.63–0.040.07
SE0.050.040.050.070.070.070.060.050.050.080.08
Heart rate (bpm)M138.05a,b131.54a133.89b140.33134.60137.56135.77128.49130.221.542.77
SE1.261.291.221.881.931.811.541.571.481.941.97

Same superscripted letters denote group difference (all p<0.05 with Bonferroni adjustment for multiple comparisons).

*p<0.05.

†One-way post hoc test for time effect between baseline and 6-mo follow-up and baseline and 12-mo follow-up.

‡Planned contrast for group difference at 6- and 12-mo follow-ups.

Goal achievement

Table 4 shows comparisons of the percentage of the participants achieving 5% weight loss goal between the comparison and intervention groups. More participants in the intervention group (31.6% [n=31]) than in the comparison group (16.2% [n=11]) achieved the weight loss goal at the 6-mo follow-up. There was no significant difference at the 12-mo follow-up. Even though there was no difference in percentage of participants with a 10% reduction in HbA1c between the comparison and intervention groups, 18.9% (n=31) and 26.2% (n=43) of all participants lowered their HbA1c more than 10% at the 6- and 12-mo follow-ups.

Table 4.

Comparisons of 5% weight loss and 10% reduction of HbA1c at 6- and 12-mo follow-ups

≥5% weight loss≥10% HbA1c reduction
6 mo12 mo6 mo12 mo
Comparison (n=68), n (%)11 (16.2)a15 (22.1)Comparison (n=68), n (%)17 (25.0)21 (30.9)
Intervention (n=98) , n (%)31 (31.6)a28 (28.6)Intervention (n=96), n (%)14 (14.6)22 (22.9)
All (n=166), n (%)42 (25.3)43 (25.9)All (n=164), n (%)31 (18.9)43 (26.2)
≥5% weight loss≥10% HbA1c reduction
6 mo12 mo6 mo12 mo
Comparison (n=68), n (%)11 (16.2)a15 (22.1)Comparison (n=68), n (%)17 (25.0)21 (30.9)
Intervention (n=98) , n (%)31 (31.6)a28 (28.6)Intervention (n=96), n (%)14 (14.6)22 (22.9)
All (n=166), n (%)42 (25.3)43 (25.9)All (n=164), n (%)31 (18.9)43 (26.2)

Same superscripted letters denote group difference (χ2 test, p<0.05).

Table 4.

Comparisons of 5% weight loss and 10% reduction of HbA1c at 6- and 12-mo follow-ups

≥5% weight loss≥10% HbA1c reduction
6 mo12 mo6 mo12 mo
Comparison (n=68), n (%)11 (16.2)a15 (22.1)Comparison (n=68), n (%)17 (25.0)21 (30.9)
Intervention (n=98) , n (%)31 (31.6)a28 (28.6)Intervention (n=96), n (%)14 (14.6)22 (22.9)
All (n=166), n (%)42 (25.3)43 (25.9)All (n=164), n (%)31 (18.9)43 (26.2)
≥5% weight loss≥10% HbA1c reduction
6 mo12 mo6 mo12 mo
Comparison (n=68), n (%)11 (16.2)a15 (22.1)Comparison (n=68), n (%)17 (25.0)21 (30.9)
Intervention (n=98) , n (%)31 (31.6)a28 (28.6)Intervention (n=96), n (%)14 (14.6)22 (22.9)
All (n=166), n (%)42 (25.3)43 (25.9)All (n=164), n (%)31 (18.9)43 (26.2)

Same superscripted letters denote group difference (χ2 test, p<0.05).

Diet and PA changes

There was a significant difference in dietary quality scores between the intervention and comparison groups at the 6- and 12-mo follow-ups, suggesting that the intervention participants had more improvement in diet quality than the comparison participants (see Table 5). Table 6 compares the differences in the levels of self-reported MPA and walking for exercise between the treatment groups. While all participants in both treatment conditions had similar levels of participation in MPA and walking at baseline, the levels of MPA and walking increased at the 6- and 12-mo follow-ups in both groups (p<0.05). The participants in the intervention group also engaged in higher levels of MPA at the 12-mo follow-up (31.3% [n=30] vs 14.9% [n=10]) and walking at the 6-mo follow-up (47.3% [n=26] vs 27.5% [n=11]) compared with the comparison group (p<0.05).

Table 5.

Changes in dietary quality scores at 6- and 12-mo follow-ups†

Change at 6 mo*Change at 12 mo*
Comparison6.31 (9.63)a8.90 (10.77)b
Intervention12.61 (12.18)a13.89 (13.36)b
All10.04 (11.60)11.83 (12.57)
Change at 6 mo*Change at 12 mo*
Comparison6.31 (9.63)a8.90 (10.77)b
Intervention12.61 (12.18)a13.89 (13.36)b
All10.04 (11.60)11.83 (12.57)

Same superscripted letters denote group difference (all p<0.05 with Bonferroni adjustment for multiple comparisons).

*p<0.05 with Bonferroni adjustment for multiple comparisons.

†One-way post hoc test for comparison of difference between baseline and month 6 and baseline and month 12.

Table 5.

Changes in dietary quality scores at 6- and 12-mo follow-ups†

Change at 6 mo*Change at 12 mo*
Comparison6.31 (9.63)a8.90 (10.77)b
Intervention12.61 (12.18)a13.89 (13.36)b
All10.04 (11.60)11.83 (12.57)
Change at 6 mo*Change at 12 mo*
Comparison6.31 (9.63)a8.90 (10.77)b
Intervention12.61 (12.18)a13.89 (13.36)b
All10.04 (11.60)11.83 (12.57)

Same superscripted letters denote group difference (all p<0.05 with Bonferroni adjustment for multiple comparisons).

*p<0.05 with Bonferroni adjustment for multiple comparisons.

†One-way post hoc test for comparison of difference between baseline and month 6 and baseline and month 12.

Table 6.

Self-reported PA at baseline and 6- and 12-mo follow-ups

Self-reported MPAaSelf-reported walkingb
<30 min/d30–59 min/d≥60 min/d<30 min/d30–59 min/d≥60 min/d
Baseline (n=184)Control (n=79)67 (89.3)2 (2.7)6 (8.0)51 (68.0)13 (17.3)11 (14.7)
Intervention (n=105)99 (90.8)8 (7.3)2 (1.8)76 (72.4)12 (11.4)17 (16.2)
6-mo follow-up (n=95)Control (n=40)23 (56.1)8 (19.5)10 (24.4)11 (27.5)18 (45.0)11 (27.5)
Intervention (n=55)37 (67.3)7 (12.7)11 (20.0)11 (20.0)18 (32.7)26 (47.3)
12-mo follow-up (n=163)Control (n=67)49 (73.1)8 (11.9)10 (14.9)18 (26.5)24 (35.3)26 (38.2)
Intervention (n=96)50 (52.1)16 (16.7)30 (31.3)21 (22.6)29 (31.2)43 (46.2)
Self-reported MPAaSelf-reported walkingb
<30 min/d30–59 min/d≥60 min/d<30 min/d30–59 min/d≥60 min/d
Baseline (n=184)Control (n=79)67 (89.3)2 (2.7)6 (8.0)51 (68.0)13 (17.3)11 (14.7)
Intervention (n=105)99 (90.8)8 (7.3)2 (1.8)76 (72.4)12 (11.4)17 (16.2)
6-mo follow-up (n=95)Control (n=40)23 (56.1)8 (19.5)10 (24.4)11 (27.5)18 (45.0)11 (27.5)
Intervention (n=55)37 (67.3)7 (12.7)11 (20.0)11 (20.0)18 (32.7)26 (47.3)
12-mo follow-up (n=163)Control (n=67)49 (73.1)8 (11.9)10 (14.9)18 (26.5)24 (35.3)26 (38.2)
Intervention (n=96)50 (52.1)16 (16.7)30 (31.3)21 (22.6)29 (31.2)43 (46.2)

Data presented as n (%).

aLinear trend for self-reported moderate physical activity at the 12-mo follow-up (Somer’s d=0.21, p<0.003).

bLinear trend for self-reported walking at the 6-mo follow-up (Somer’s d=0.17, p<0.07).

Table 6.

Self-reported PA at baseline and 6- and 12-mo follow-ups

Self-reported MPAaSelf-reported walkingb
<30 min/d30–59 min/d≥60 min/d<30 min/d30–59 min/d≥60 min/d
Baseline (n=184)Control (n=79)67 (89.3)2 (2.7)6 (8.0)51 (68.0)13 (17.3)11 (14.7)
Intervention (n=105)99 (90.8)8 (7.3)2 (1.8)76 (72.4)12 (11.4)17 (16.2)
6-mo follow-up (n=95)Control (n=40)23 (56.1)8 (19.5)10 (24.4)11 (27.5)18 (45.0)11 (27.5)
Intervention (n=55)37 (67.3)7 (12.7)11 (20.0)11 (20.0)18 (32.7)26 (47.3)
12-mo follow-up (n=163)Control (n=67)49 (73.1)8 (11.9)10 (14.9)18 (26.5)24 (35.3)26 (38.2)
Intervention (n=96)50 (52.1)16 (16.7)30 (31.3)21 (22.6)29 (31.2)43 (46.2)
Self-reported MPAaSelf-reported walkingb
<30 min/d30–59 min/d≥60 min/d<30 min/d30–59 min/d≥60 min/d
Baseline (n=184)Control (n=79)67 (89.3)2 (2.7)6 (8.0)51 (68.0)13 (17.3)11 (14.7)
Intervention (n=105)99 (90.8)8 (7.3)2 (1.8)76 (72.4)12 (11.4)17 (16.2)
6-mo follow-up (n=95)Control (n=40)23 (56.1)8 (19.5)10 (24.4)11 (27.5)18 (45.0)11 (27.5)
Intervention (n=55)37 (67.3)7 (12.7)11 (20.0)11 (20.0)18 (32.7)26 (47.3)
12-mo follow-up (n=163)Control (n=67)49 (73.1)8 (11.9)10 (14.9)18 (26.5)24 (35.3)26 (38.2)
Intervention (n=96)50 (52.1)16 (16.7)30 (31.3)21 (22.6)29 (31.2)43 (46.2)

Data presented as n (%).

aLinear trend for self-reported moderate physical activity at the 12-mo follow-up (Somer’s d=0.21, p<0.003).

bLinear trend for self-reported walking at the 6-mo follow-up (Somer’s d=0.17, p<0.07).

Trial participation

The average attendance of the 23 sessions was 67.5%, with 66 intervention participants attending 70% or more of the sessions. However, attending 70% of the sessions was not associated with improvement in the outcome measures at the 6- and 12-mo follow-ups (data not shown). There was no unintended effect reported by the study participants (Table 7).

Table 7.

Health education class attendance*

Treatment groupSessions attended (n), mean (SD)†Sessions attended (%), mean (SD)†≥70% of sessions attended, %‡
Comparison3.46 (1.64)a57.7 (27.4)a31.0a
Intervention15.53 (7.60)a67.5 (33.0)a66.0a
Treatment groupSessions attended (n), mean (SD)†Sessions attended (%), mean (SD)†≥70% of sessions attended, %‡
Comparison3.46 (1.64)a57.7 (27.4)a31.0a
Intervention15.53 (7.60)a67.5 (33.0)a66.0a

Same superscripted letters denote group difference (p<0.05).

*Intervention group had 23 health education classes and small-group meetings; comparison group had 6 health education sessions.

†One-way F test.

‡χ2 test.

Table 7.

Health education class attendance*

Treatment groupSessions attended (n), mean (SD)†Sessions attended (%), mean (SD)†≥70% of sessions attended, %‡
Comparison3.46 (1.64)a57.7 (27.4)a31.0a
Intervention15.53 (7.60)a67.5 (33.0)a66.0a
Treatment groupSessions attended (n), mean (SD)†Sessions attended (%), mean (SD)†≥70% of sessions attended, %‡
Comparison3.46 (1.64)a57.7 (27.4)a31.0a
Intervention15.53 (7.60)a67.5 (33.0)a66.0a

Same superscripted letters denote group difference (p<0.05).

*Intervention group had 23 health education classes and small-group meetings; comparison group had 6 health education sessions.

†One-way F test.

‡χ2 test.

Discussion

The findings of this RCT demonstrate that Chinese women at risk for diabetes significantly lowered their body weight and BMI after participation in a 6-mo lifestyle intervention program at the 6-mo follow-up compared with participants who received general healthy lifestyle education. However, the group difference had disappeared at the 12-mo follow-up. There was no other significant difference in the outcome measures. However, all of the outcome measures except fasting glucose improved from baseline to the 6- and 12-mo follow-ups in the intervention as well as comparison participants.

Translation studies of DPP with an RCT design are rare in China. Although the CDQDPOS was among the first studies that demonstrated the efficacy of lifestyle intervention to prevent diabetes in adults with pre-diabetes,4 the finding has not been tested using a translation research paradigm to examine its effectiveness and scalability in community settings.17 The PATH intervention closely mimicked the key concepts and components of the DPP lifestyle intervention5 that has been successfully adapted for different population groups and settings in the USA and other countries.7,18 In addition, we adapted the DPP’s intervention strategies and activities to accommodate both cultural and lifestyle preferences of Chinese women. Intervention impacts on body weight, dietary quality and PA confirmed the PATH intervention has produced desirable behavioral changes, as anticipated.2 High levels of program compliance measured by attendance suggest that the program was feasible and acceptable regarding delivery format, behavioral intervention strategies and program activities. The dropout rate in the study was consistent with those reported in other translation studies.19 Together, the evidence suggests that we have successfully adapted an evidence-based intervention for implementation in Chinese CHCs, even though we were unable to demonstrate its effectiveness in some important outcome measures.20 Future studies should compare the effectiveness of the CDQDPOS and DPP using the translation research paradigm.

Weight loss (5–7%) is the primary indicator of success for risk reduction in diabetes prevention trials as well as translation studies.19 However, studies in addition to ours have reported weight loss of less than 5% in ‘real-world’ settings in non-Western countries.18,21 The PATH participants showed a consistent trend of reduced weight, BMI and waist circumference over time as well. The magnitude of reduction, however, was considerably smaller compared with Western studies. This is consistent with diabetes prevention studies conducted in Asian populations. No significant weight loss was reported in the study participants at the 6-y evaluation in the CDQDPOS,4 and weight loss was also small in Japanese adults with pre-diabetes in two Japanese DPP translation trials.22,23 While the average BMI was ≥35 in Western studies, the average BMI in our study and the Japanese studies was less than 28. Therefore, as important as it is to lose weight, the expected amount would be less than the 5% in populations with a lower overall body mass compared with DPP translation studies in Western populations. It is also interesting to note that PATH program attendance (attending ≥70% of sessions) did not affect the outcomes, contrary to findings in other studies.7,18 The Chinese women in the study tended to be older, have a low level of education, to not work outside the home and to have childcare responsibilities. It is unclear how these participant characteristics might have influenced their responsiveness to the intervention.24 We also want to note that the PATH curriculum started with PA followed by nutrition education, whereas studies that started with nutrition education reported improved long-term weight loss in Western populations. Finally, lack of a maintenance program may contribute to the diminished program effects at the 12-mo follow-up. Continued participant support was shown to be critical in achieving long-term effects among community-based lifestyle intervention participants, whereas in our study we offered no maintenance program from month 6 to month 12.25

In general, changes in clinical measures such as HbA1c and fasting glucose were minimal in DPP translation studies.26 A recent meta-analysis found that the use of lifestyle interventions in routine clinical practice positively influenced body weight–related measures but not clinical measures in patients at high risk for diabetes.27 In our study there is a non-significant favorable trend of a reduction in HbA1c in the intervention participants, while fasting glucose increased over the study period. Others also reported an increase in fasting glucose in intervention participants that can be attributed to regression to the mean over time.28 Among the two clinical indicators, more intervention participants reached the 5% weight loss goal at the 6-mo follow-up, which is consistent with previous studies.19 No other significant difference was found, although both groups showed improvement in the clinical indicators.

We offered six general healthy lifestyle education classes to the comparison group, which were well attended. This enhanced treatment over the traditional control treatment led the comparison participants to engage in behavioral changes. Anecdotal information revealed that the provision of health screenings and providing a free pedometer motivated the comparison participants to change their lifestyle, resulting in an improvement in the outcome measures and process measures in the comparison participants. Future research should explore this minimalistic approach in resource-poor communities in developing countries.24

Improvement in diet (reduced calorie and fat intake) and PA (150 min of MVPA/wk) and frequent self-monitoring were closely associated with weight loss and a reduced incidence of diabetes in DPP29 and DPP translation studies.30,31 Less is known about the effectiveness of lifestyle interventions that are based on Western lifestyles and healthcare systems in non-Western low- and middle-income countries.32 We were unable to quantify the changes and achievement of goals in diet and PA accurately with the use of self-reported measures in our study. Nevertheless, we found consistent improvement in dietary quality and PA in the intervention participants, suggesting that lifestyle interventions based on behavior change theories can be applied to the Chinese population.

There were several limitations in our study that might have affected the generalizability and validity of the study. First, the study was underpowered due to not recruiting the number of participants (57% of targeted sample) based on the power estimation. We encountered many challenges in recruiting study participants, which could be improved by better recruitment outreach and participant education and using multiple recruitment strategies. Some eligible patients refused to participate because of concern about the legitimacy of the study or time conflicts with their family or work obligations. Another unanticipated problem was that many of the eligible patients could not be reached with the contact information in the database at the CHCs, which was the main source of the participant pool. Although the poor recruitment and participation rate did appear to be systematic, the smaller sample size failed to provide adequate power to test the research questions and therefore limited the generalizability of the study findings. Second, PATH intervention only lasted 6 mo, compared with an intervention duration of 6–12 mo in other translation studies.18,32 Future studies should test interventions with a longer duration and a maintenance program in Chinese populations. Third, there were concerns about the accuracy of blood assays that were performed in the regional hospital laboratory in three separate batches without a calibration protocol. As a result, there were large variations and standard deviations in the measurements. Finally, there were technical difficulties and inconsistencies in implementing the fitness test protocol that led to underestimation of heart rates in some participants.

Conclusion

With the global increase in diabetes rates, cultural adaptation and translation of evidence-based interventions are urgently needed. Findings from our study demonstrate that the PATH intervention is feasible and acceptable for implementation in Chinese CHCs and holds great promise to prevent diabetes in Chinese residents at risk for diabetes. But it should be noted that the effect sizes are small. Future implementation studies are needed to test PATH effectiveness in a large RCT with refinement of the intervention based on feedback from this study.

Authors’ contributions: ZY and MS (project co-directors) were responsible for conceptualizing the study and securing the funding for the study. ZY, MH, YF and JP were responsible for development of the intervention program and data collection protocol and staff training. JP supervised the study implementation and data collection. ZY, JP and RJ were responsible for database management and data analysis. All authors participated in the interpretation of results and preparation of the manuscript. The study protocol is available upon request to ZY. ZY and MS are guarantors of the paper.

Acknowledgements: The authors acknowledge the support of Shanxi Yuci Public Health Bureau and the Center for Disease Prevention in the development and implementation of the study. Heartfelt appreciation also goes to the Yuci residents who participated in the study. Finally, it would have been impossible to complete the study without the hard work and dedication of the Community Health Educators and the Evergreen staff at the Yuci office. The PATH intervention program was based on a translation planning study conducted in San Antonio, TX, USA that was supported by the National Institutes of Health (NIH R34DK084203 to ZY).

Funding: This project is supported by a BRIDGES Grant (ST10-019) from the International Diabetes Federation. BRIDGES, an International Diabetes Federation project, is supported by an educational grant from Lilly Diabetes. The authors also received a gift from the Coca Cola Company (Atlanta, GA, USA) to support the project.

Competing interests: None declared.

Ethical approval: The study protocol was approved by the Institutional Review Boards of the University of Texas at San Antonio and North Dakota State University.

References

1

Chen
P
,
Chai
J
,
Cheng
J
et al. .
A smart web aid for preventing diabetes in rural China: preliminary findings and lessons
.
J Med Internet Res
2014
;
16
(
4
):
e98
.

2

Dawson Rose
C
,
Gutin
SA
,
Reyes
M
.
Adapting positive prevention interventions for international settings: applying U.S. evidence to epidemics in developing countries
.
J Assoc Nurses AIDS Care
2011
;
22
(
1
):
38
52
.

3

Nierkens
V
,
Hartman
MA
,
Nicolaou
M
et al. .
Effectiveness of cultural adaptations of interventions aimed at smoking cessation, diet, and/or physical activity in ethnic minorities. A systematic review
.
PLoS One
2013
;
8
(
10
):
e73373
.

4

Pan
XR
,
Li
GW
,
Hu
YH
et al. .
Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study
.
Diabetes Care
1997
;
20
(
4
):
537
44
.

5

Diabetes Prevention Program Research Group
.
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
.
N Engl J Med
2002
;
346
(
6
):
393
403
.

6

Tuomilehto
J
,
Lindström
J
,
Eriksson
JG
et al. .
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance
.
N Engl J Med
2001
;
344
(
18
):
1343
50
.

7

Ali
MK
,
Echouffo-Tcheugui
JB
,
Williamson
DF
.
How effective were lifestyle interventions in real-world settings that were modeled on the Diabetes Prevention Program?
Health Aff (Millwood)
2012
;
31
(
1
):
67
75
.

8

Central Committee of the Communist Party of China State Council
. Opinions of the CPC Central Committee and the State Council on deepening the health care system reform.
2012
. http://www.china.org.cn/government/scio-press-conferences/2009-04/09/content_17575378.htm.

9

Macfarlane
DJ
,
Lee
CC
,
Ho
EY
et al. .
Reliability and validity of the Chinese version of IPAQ (short, last 7 days)
.
J Sci Med Sport
2007
;
10
(
1
):
45
51
.

10

Montoye
HJ
,
Willis
PW
3rd
,
Cunningham
DA
et al. .
Heart rate response to a modified Harvard step test: males and females, age 10–69
.
Res Q
1969
;
40
(
1
):
153
62
.

11

Deng
HB
,
MacFarlane
DJ
,
Thomas
GN
.
Reliability and validity of the IPAQ-Chinese: the Guangzhou Biobank Cohort Study
.
Med Sci Sports Exerc
2008
;
40
(
2
):
303
307
.

12

Yang
XG
,
Kong
L-Z
,
Xiang
H-D
et al. .
China National Nutrition and Health Survey study design
.
Chin J Epidemiol
2005
;
26
(
7
):
471
474
.

13

Kramer
MK
,
McWilliams
JR
,
Chen
H-Y
et al. .
A community-based diabetes prevention program
.
Diabetes Educ
2011
;
37
(
5
):
659
68
.

14

Sosa
ET
,
Biediger-Friedman
L
,
Yin
Z
.
Lessons learned from training of Promotores de Salud for obesity and diabetes prevention
.
J Health Dispar Res Pract
2013
;
6
(
1
):
1
.

15

Chinese Nutrition Society
.
Dietary guidelines and the Food Guide Pagoda
.
J Am Diet Assoc
2000
;
100
(
8
):
886
887
.

16

China Diabetes Society
. China guideline for type 2 diabetes. Beijing, China: China Diabetes Society;
2010
.

17

Feng
R
,
Li
K
,
Cheng
J
et al. .
Toward integrated and sustainable prevention against diabetes in rural China: study rationale and protocol of eCROPS
.
BMC Endocr Disord
2013
;
13
:
28
.

18

Dunkley
AJ
,
Bodicoat
DH
,
Greaves
CJ
et al. .
Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta-analysis
.
Diabetes Care
2014
;
37
(
4
):
922
33
.

19

Baker
MK
,
Simpson
K
,
Lloyd
B
et al. .
Behavioral strategies in diabetes prevention programs: a systematic review of randomized controlled trials
.
Diabetes Res Clin Pract
2011
;
91
(
1
):
1
12
.

20

McKleroy
VS
,
Galbraith
JS
,
Cummings
B
et al. .
Adapting evidence-based behavioral interventions for new settings and target populations
.
AIDS Educ Prev
2006
;
18
(
4 Suppl A
):
59
73
.

21

Whittemore
R
.
A systematic review of the translational research on the Diabetes Prevention Program
.
Transl Behav Med
2011
;
1
(
3
):
480
91
.

22

Sakane
N
,
Sato
J
,
Tsushita
K
et al. .
Prevention of type 2 diabetes in a primary healthcare setting: three-year results of lifestyle intervention in Japanese subjects with impaired glucose tolerance
.
BMC Public Health
2011
;
11
(
1
):
40
.

23

Saito
T
,
Watanabe
M
,
Nishida
J
et al. .
Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial
.
Arch Intern Med
2011
;
171
(
15
):
1352
60
.

24

Laws
RA
,
St. George
AB
,
Rychetnik
L
et al. .
Diabetes prevention research: a systematic review of external validity in lifestyle interventions
.
Am J Prev Med
2012
;
43
(
2
):
205
14
.

25

Yoon
U
,
Kwok
LL
,
Magkidis
A
.
Efficacy of lifestyle interventions in reducing diabetes incidence in patients with impaired glucose tolerance: a systematic review of randomized controlled trials
.
Metabolism
2013
;
62
(
2
):
303
14
.

26

Johnson
M
,
Jones
R
,
Freeman
C
et al. .
Can diabetes prevention programmes be translated effectively into real-world settings and still deliver improved outcomes? A synthesis of evidence
.
Diabetic Med
2013
;
30
(
1
):
3
15
.

27

Cardona-Morrell
M
,
Rychetnik
L
,
Morrell
SL
et al. .
Reduction of diabetes risk in routine clinical practice: are physical activity and nutrition interventions feasible and are the outcomes from reference trials replicable? A systematic review and meta-analysis
.
BMC Public Health
2010
;
10
(
1
):
1
17
.

28

Seidel
MC
,
Powell
RO
,
Zgibor
JC
et al. .
Translating the Diabetes Prevention Program into an urban medically underserved community: a nonrandomized prospective intervention study
.
Diabetes Care
2008
;
31
(
4
):
684
689
.

29

Hamman
RF
,
Wing
RR
,
Edelstein
SL
et al. .
Effect of weight loss with lifestyle intervention on risk of diabetes
.
Diabetes Care
2006
;
29
(
9
):
2102
07
.

30

Harwell
TS
,
Vanderwood
KK
,
Hall
TO
et al. .
Factors associated with achieving a weight loss goal among participants in an adapted Diabetes Prevention Program
.
Prim Care Diabetes
2011
;
5
(
2
):
125
129
.

31

Horton
ES
.
Effects of lifestyle changes to reduce risks of diabetes and associated cardiovascular risks: results from large scale efficacy trials
.
Obesity (Silver Spring)
2009
;
17
(
Suppl 3
):
S43
48
.

32

Aziz
Z
,
Absetz
P
,
Oldroyd
J
et al. .
A systematic review of real-world diabetes prevention programs: learnings from the last 15 years
.
Implement Sci
2015
;
10
:
1
17
.

Author notes

The authors wish it to be known that in their opinion the first and last authors should be regarded as joint first authors.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/about_us/legal/notices)

Comments

0 Comments
Submit a comment
You have entered an invalid code
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.